National Institute of Allergy and Infectious Diseases (NIAID)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Inclusion Criteria: * Documented HIV-1 infection * Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use * HIV-1 RNA \>1000 copies/mL within 60 days prior to study entry * Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence * At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance * Ade…
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.
Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.
Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.